Regulus Therapeutics Inc. (RGLS) Financials
Stock symbol RGLS is outdated, potentially delisted? Maybe it is available on other exchange?
RGLS Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Sept. 30, 2023 | 37.7 million | 9.5 million |
| June 30, 2023 | 43.6 million | 9.7 million |
| March 31, 2023 | 37.0 million | 10.4 million |
| Dec. 31, 2022 | 46.7 million | 13.4 million |
RGLS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Sept. 30, 2023 | -6.8 million | 973000 |
| June 30, 2023 | -6.3 million | 382000 |
| March 31, 2023 | -8.1 million | 410000 |
| Dec. 31, 2022 | -6.3 million | 397000 |
RGLS Net Income
No data available :(
RGLS Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Sept. 30, 2023 | 30.8 million | - | 1.2 million |
| June 30, 2023 | 37.3 million | - | 1.4 million |
| March 31, 2023 | 30.3 million | - | 1.6 million |
| Dec. 31, 2022 | 39.2 million | - | 1.8 million |
RGLS Shares Outstanding
RGLS Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Sept. 30, 2023 | 541000 | 5.5 million | 2.6 million | - |
| June 30, 2023 | - | 5.0 million | 2.3 million | - |
| March 31, 2023 | 1000 | 4.9 million | 2.4 million | - |
| Dec. 31, 2022 | 63000 | 4.7 million | 2.2 million | - |
RGLS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Sept. 30, 2023 | - | 56000 |
| June 30, 2023 | - | 47000 |
| March 31, 2023 | - | 48000 |
| Dec. 31, 2022 | - | 33000 |
RGLS
Price: $8.16
52 week price:
Earnings Per Share: -0.68 USD
P/E Ratio: -12
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 68300
Ebitda: -14.7 millionMarket Capitalization: 565.0 million